| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| 500mg |
| ln Vitro |
Zonisamideodium (10, 50, 100, 200 µM; 24 hours) enhances the viability of SH-SY5Y cells by anti-apoptotic actions [1]. Zonisamideodium (100 µM; 24 hours) has neuroprotective properties in PD cell models. (PD: Parkinson's disease) [1]. Zonisamideodium (100 µM; 24 hours) lowers the levels of pro-apoptotic markers and upregulates the levels of MnSOD (overexpression of MnSOD attenuates MPTP toxicity and protects cells from apoptosis) [1]. Zonisamide sodium (0.1, 0.3, 1 μM; 24 h) reduces myocardial hypertrophy and fibrosis in vitro [3]. Zonisamideodium substantially enhances the expression of Hrd1 in Ang II-treated NRCM [3].
|
|---|---|
| ln Vivo |
An amygdala seizure paradigm generated by FeCl3 that is chronic is protected against seizures by zonisamide sodium (40 mg/kg; i.p.; once daily for 14 days) [2]. In rats with abdominal aortic coarctation (AAC), zonisamide sodium (14, 28, 56 mg/kg; intraperitoneal injection; single daily dose for 6 weeks) decreases cardiac hypertrophy and enhances cardiac function [3]. In the hearts of AAC rats, zonisamide sodium (14, 28, 56 mg/kg; intraperitoneal injection; once daily for 6 weeks) increases Hrd1 expression and speeds up ERAD [3].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: SH-SY5Y Cell Tested Concentrations: 10, 50, 100, 200 µM Incubation Duration: 24 hrs (hours) Experimental Results: Induced cell viability to increase, 100 µM has the best effect. Exhibits neuroprotective effects on SH-SY5Y cells (PD cell model) at 100 µM. Apoptosis analysis [1] Cell Types: SH-SY5Y Cell Tested Concentrations: 100 µM Incubation Duration: 24 h Experimental Results: demonstrated anti-apoptotic effect. RT-PCR[3] Cell Types: NRCM and cardiac fibroblasts (exposed to Ang II for cardiomyocyte hypertrophy and fibrosis model) Tested Concentrations: 0.1, 0.3, 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: Atrial natriuretic factor ( ANF) expression was diminished and myosin heavy chain beta (β-MHC), but myosin heavy chain alpha (α-MHC) expression was increased in NRCM. Cardiac expression of the fibrosis-related gene collagen 1A1 (Col1A1) is diminished in cardiac fibroblasts. Western Blot Analysis[1] Cell Types: SH-SY5Y Cell Tested Concentrations: 100 µM Incubation Duration: 24 h Experimental Results: Reduce the levels of cleaved caspase-9, -3 and p-JN |
| Animal Protocol |
Animal/Disease Models: Male Wistar rat (200-250 g; FeCl3-induced chronic amygdala seizures) [2].
Doses: 40 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day for 14 days. Experimental Results: demonstrated anti-epileptic activity. The GABA transporter GAT-1 was Dramatically downregulated in the hippocampus. Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rat (100-120 g; cardiac hypertrophy model) [3]. Doses: 14, 28, 56 mg/kg (dissolved in 1% DMSO) Route of Administration: intraperitoneal (ip) injection; one time/day for 6 weeks. Experimental Results: Significant reduction in cardiac hypertrophy and fibrosis. Left ventricular ejection fraction (EF), fractional shortening (FS) and E/A ratio were increased. Dramatically increased Hrd1 expression in AAC rat hearts. |
| References |
[1]. Kawajiri S, et al. Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neurosci Lett. 2010 Sep 6;481(2):88-91.
[2]. Ueda Y, et al. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):1-6. [3]. Wu Q, et al. Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress. Acta Pharmacol Sin. 2021 Oct;42(10):1587-1597. [4]. De Simone G, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. |
| Molecular Formula |
C8H7N2O3S-.NA+
|
|---|---|
| Molecular Weight |
234.20758
|
| CAS # |
68291-98-5
|
| Related CAS # |
Zonisamide;68291-97-4
|
| SMILES |
O=S(CC1=NOC2=C1C=CC=C2)(N)=O.[Na+]
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2697 mL | 21.3484 mL | 42.6967 mL | |
| 5 mM | 0.8539 mL | 4.2697 mL | 8.5393 mL | |
| 10 mM | 0.4270 mL | 2.1348 mL | 4.2697 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
